Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) released its earnings results on Thursday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports. Vanda Pharmaceuticals had a negative net margin of 8.59% and a negative return on equity of 3.02%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock traded down $0.05 during midday trading on Thursday, reaching $4.70. 925,757 shares of the company’s stock traded hands, compared to its average volume of 578,641. The stock has a 50 day moving average of $4.63 and a 200-day moving average of $4.87. Vanda Pharmaceuticals has a 12 month low of $3.71 and a 12 month high of $6.75. The company has a market cap of $274.06 million, a PE ratio of -16.79 and a beta of 0.74.

Analyst Ratings Changes

VNDA has been the topic of a number of research analyst reports. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 4th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.